<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02765399</url>
  </required_header>
  <id_info>
    <org_study_id>LIRA</org_study_id>
    <nct_id>NCT02765399</nct_id>
  </id_info>
  <brief_title>The Effect of Liraglutide Treatment on Postprandial Chylomicron and VLDL Kinetics, Liver Fat and de Novo Lipogenesis</brief_title>
  <official_title>The Effect of Liraglutide Treatment on Postprandial Chylomicron and VLDL Kinetics, Liver Fat and de Novo Lipogenesis - a Single-center Randomized Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Helsinki University Central Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GÃ¶teborg University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Helsinki University Central Hospital</source>
  <brief_summary>
    <textblock>
      This study aims to evaluate the mechanisms underlying the effect of incretin therapy on
      lipoprotein metabolism in subjects with type 2 diabetes and to study the effect of
      liraglutide on hepatic de novo lipogenesis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The well recognized dyslipidemia in people with type 2 diabetes consists of high fasting and
      non-fasting plasma triglycerides (TG), low high-density lipoprotein (HDL) -cholesterol and
      preponderance of small dense low-density lipoprotein (LDL) particles nominated as the
      atherogenic lipid triad. Humans are mostly in a postprandial rather than fasting state and
      therefore non-fasting TG values reflect more accurately the continuous exposure of arterial
      wall to triglyceride rich lipoproteins (TRLs) and more importantly, to substantial
      cholesterol load that these particles deliver.

      Postprandial lipemia is highly prevalent even in type 2 diabetes patients with normal fasting
      TG concentrations. Intestinal overproduction of chylomicrons (CMs) and the structural protein
      apolipoprotein (apo)-B48 has been identified as an integral feature of postprandial lipemia
      in type 2 diabetes and insulin resistance. It is clinically important to elucidate the
      mechanism for delayed postprandial lipemia and the interactions between dysglycemia and
      dyslipidemia in type 2 diabetes patients.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 1, 2015</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in liver fat content</measure>
    <time_frame>4 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma triglyceride (TG) area under curve (AUC)</measure>
    <time_frame>4 months</time_frame>
    <description>Before vs after intervention: postprandial plasma TG summary measure expressed as AUC (baseline to 8 hours) after oral fat tolerance test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in hepatic de novo lipogenesis</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ApoB100/apoB48 kinetics</measure>
    <time_frame>4 months</time_frame>
    <description>Before vs. after intervention: apoB100/apoB48 secretion rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ApoB100/apoB48 kinetics</measure>
    <time_frame>4 months</time_frame>
    <description>Before vs. after intervention: apoB100/apoB48 fractional catabolic rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolic parameters</measure>
    <time_frame>4 months</time_frame>
    <description>Before vs. after intervention: postprandial lipids and apolipoproteins (8 hours) after oral fat tolerance test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolic parameters</measure>
    <time_frame>4 months</time_frame>
    <description>Before vs. after intervention: glycemic control</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolic parameters</measure>
    <time_frame>4 months</time_frame>
    <description>Before vs. after intervention: plasma lipidomics</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Liraglutide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Liraglutide subcutaneous injection once daily with following dose escalation:
liraglutide 0.6 mg once daily for one week; liraglutide 1.2 mg once daily for one week and thereafter liraglutide 1.8 mg once daily for 3.5 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo subcutaneous injection once daily with following dose escalation:
placebo 0.1 ml once daily for one week; placebo 0.2 ml once daily for one week and thereafter placebo 0.3 ml once daily for 3.5 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liraglutide</intervention_name>
    <arm_group_label>Liraglutide</arm_group_label>
    <other_name>Victoza</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with type 2 diabetes treated with a lifestyle or metformin (any dose)

          -  waist circumference &gt; 88 cm in women and &gt; 92 cm in men

          -  BMI 27-40 kg/m2

          -  triglycerides between 1.0 - 4.0 mmol/L

          -  LDL &lt; 4.5 mmol/l

        Exclusion Criteria:

          -  Type 1 diabetes

          -  Apo E2/2 phenotype

          -  ALT/AST &gt; 3x ULN

          -  GFR &lt; 60 ml/min, clinically significant TSH outside normal range

          -  Lipid-lowering drugs other than statins within 6 months

          -  Current treatment with pioglitazone, insulin, sulphonylureas, gliptins, glinides,
             SGLT-2 inhibitors or thiazide diuretics (at a dose of &gt; 25 mg / day)

          -  Blood pressure &gt; 160 mmHg systolic and/or &gt; 105 diastolic

          -  History of pancreatitis or stomach / other major bleeding, thyroid neoplasia,
             persistent hypothyroidism or persistent hyperthyroidism

          -  Any medical condition that puts the patient in the risk of dehydration

          -  Concurrent medical condition that may interfere with the interpretation of efficacy
             and safety data during the study.

          -  Females of childbearing potential who are not using adequate contraceptive methods

          -  Subjects who have experienced side-effects previously from GLP-1 agonists

          -  Non-compliance or withdrawal of consent

          -  Any information or clinical event described in liraglutide SPC that is a
             contraindication for the use of liraglutide
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Niina Matikainen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Senior Endocrinologist</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Helsinki University Central Hospital</name>
      <address>
        <city>Helsinki</city>
        <zip>00029</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 2, 2016</study_first_submitted>
  <study_first_submitted_qc>May 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 6, 2016</study_first_posted>
  <last_update_submitted>January 24, 2018</last_update_submitted>
  <last_update_submitted_qc>January 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Helsinki University Central Hospital</investigator_affiliation>
    <investigator_full_name>Niina Matikainen</investigator_full_name>
    <investigator_title>Senior Endocrinologist</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liraglutide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

